Nicox S.A. (NICXF)
Nicox S.A.
Sundesk Sophia Antipolis
Emerald Square Batiment C rue Evariste Galois
Valbonne 06410
France
33 4 97 24 53 00
https://www.nicox.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 28
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Gavin M. Spencer | CEO & Director | N/A | N/A | 1970 |
| Ms. Sandrine Gestin | Vice President of Finance | N/A | N/A | 1967 |
| Mr. Doug Hubatsch | Executive VP & Chief Scientific Officer | N/A | N/A | 1967 |
| Dr. Ramesh Krishnamoorthy | Senior Director and Head of Late Stage CMC & Quality Control | N/A | N/A | N/A |
| Dr. Jose Boyer | Consultant | N/A | N/A | N/A |
Description
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
Corporate Governance
Nicox S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
